Immunic, Inc. Announces Conference Participation for November
NEW YORK — Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in key industry and investor conferences this coming November.
Details of Upcoming Conferences
Immunic is set to join various industry forums including:
BIO-Europe Conference
From November 3-5, key members of the Immunic team, including CEO Daniel Vitt, Ph.D., Chief Scientific Officer Hella Kohlhof, Ph.D., and Vice President of Investor Relations and Communications Jessica Breu, will engage in partnering activities at the BIO-Europe Conference held in Vienna, Austria. Interested parties can utilize the official partnering system to schedule meetings.
Jefferies Global Healthcare Conference
Additionally, Dr. Vitt, alongside Jason Tardio, President and COO of Immunic, will host one-on-one meetings in London on November 19-20. This event is in conjunction with the Jefferies Global Healthcare Conference - London. Stakeholders should reach out to Jessica Breu to arrange discussions during this opportunity.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) specializes in small molecule therapies aimed at treating chronic inflammatory and autoimmune conditions. Their lead candidate, vidofludimus calcium (IMU-838), is undergoing phase 3 trials targeting relapsing multiple sclerosis, showcasing promising therapeutic activity based on prior phase 2 results. This innovative therapy works on neuroprotection while also addressing inflammation.
Moreover, Immunic is developing IMU-856 to enhance intestinal barrier function, which may benefit various gastrointestinal disorders. Their commitment also includes developing IMU-381, currently in preclinical stages, designed to meet the needs of patients with gastrointestinal issues.
Further Information
For more information about Immunic's initiatives and upcoming presentations, please visit their official website. The firm continues to advance its projects and engage with the healthcare investor community to share its vision and developments.
Frequently Asked Questions
What is the focus of Immunic, Inc.?
Immunic, Inc. is focused on developing small molecule therapies for chronic inflammatory and autoimmune diseases.
What major conferences will Immunic participate in this November?
The company will be attending the BIO-Europe Conference from November 3-5 and the Jefferies Global Healthcare Conference on November 19-20.
Who are the key personnel attending these events?
Key personnel include CEO Daniel Vitt and President and COO Jason Tardio, along with Jessica Breu, the Vice President of Investor Relations.
What is vidofludimus calcium?
Vidofludimus calcium (IMU-838) is Immunic's lead therapeutic candidate, currently in phase 3 clinical trials for treating relapsing multiple sclerosis.
How can I schedule a meeting with Immunic's representatives?
Interested individuals should contact Jessica Breu or utilize the digital partnering platform for the conferences.